カンバヤシ　ケイゴ   Kanbayashi Keigo   神林　敬悟    所属   医学部 医学科（東京女子医科大学病院）    職種   助手
言語種別	日本語
発表タイトル	Underdiagnosis and Under Treatment of Heterozygous Familial Hypercholesterelemia in Cardiovascular Diseases
会議名	第81回日本循環器学会学術集会
主催者	日本循環器学会
学会区分	全国規模の学会
発表形式	ポスター掲示
講演区分	一般
発表者・共同発表者	◎関口治樹, 佐藤加代子, 神林敬悟, 飯田達郎, 高野真弓, 坂井晶子, 萩原誠久
発表年月日	2017/03/19
開催地 （都市, 国名）	金沢市
学会抄録	第81回日本循環器学会学術集会　プログラム集 461
概要	BACKGROUND: Heterozygous familial hypercholesterolaemia (hFH) is most common genetic disease and cause of premature cardiovascular disease(CVD). However, the diagnosis rate is less than 0.1% in Japan. AIMS: We examined the patients hospitalized for CVD and evaluate the extent to which hFH is underdiagnosed and undertreated. METHODS: We analyzed the consecutive 553 patients hospitalized for CVD from 2013 to 2015. To investigate the prevalence of hFH, we focused on the patients with high LDL‒C levels more than 140mg/dL in these CVD patients. RESULTS: Sixty‒four patients had high LDL‒C levels. In those, 37 (6.7% of all CVD) patients were diagnosed as hFH (62.9±15.4years) according to FH guidelines. We compared lipids profiles between hFH and the patients with hypercholesterolemia (DL,68.3±15.0years). The hFH patients had significantly higher T‒cho levels (243.8±32.3mg/dL, 224.1±15.0mg/dL, P<0.01, respectively) and LDL‒C levels (172.5±24.2mg/dL, 152.3±8.2mg/dL, P<0.01, respectively) than DL patients. Blood pressure, EF, TG, HDL‒C, Cre, BNP, CRP were not significant difference between hFH and DL. Furthermore, 32.4% of hFH had the past history of CVD. However, just 27% of hFH were treated with statins on admission, and also only 0.05% of hFH had a definitive diagnosis at discharge. CONCLUSION: Owing to severe underdiagnosis and under treatment of hFH, there is an urgent need for diagnostic screening together with early and aggressive treatments of high risk condition of future cardiovascular events.